Metabotropic glutamate receptors and the control of chronic pain

Santina Chiechio, Ferdinando Nicoletti

Research output: Contribution to journalArticlepeer-review


Over the past two decades metabotropic glutamate (mGlu) receptor ligands have been investigated for their potential therapeutic effects in different disorders of the central nervous system (CNS), including anxiety, depression, schizophrenia, and neurodegenerative diseases. In addition, it has been widely demonstrated that mGlu receptors are able to modulate pain transmission both in inflammatory and neuropathic pain models. A large number of preclinical studies combining the use of selective ligands with the knockout strategy have revealed more details about the role of the different mGlu receptor subtypes in the modulation of pain information. This review will address the role of mGlu receptors in pain sensitivity focusing on different strategies to achieve pain control by targeting specific mGlu receptor subtypes. Specifically, pharmacological interventions aimed at inhibiting group I mGlu receptor-mediated signaling and/or potentiating groups II and III mGlu receptor signaling together with an epigenetic approach leading to an increased expression of mGlu2 receptors will be discussed.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalCurrent Opinion in Pharmacology
Issue number1
Publication statusPublished - Feb 2012

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Metabotropic glutamate receptors and the control of chronic pain'. Together they form a unique fingerprint.

Cite this